Monument Tx is an England-based biotechnology company that researches and develops novel drugs for the treatment of central nervous system diseases... Read more
Monument Tx is an England-based biotechnology company that researches and develops novel drugs for the treatment of central nervous system diseases... Read more
News
Apr 30, 2026
EIN Presswire
Press Release: Monument Therapeutics : Monument Tx Announces US Patent for MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Mar 10, 2026
EIN Presswire
Press Release: Monument Therapeutics : Monument Therapeutics Announces First Patient Dosed in Trial of MT1988 in Patients at Clinical High Risk for Psychosis
Aug 20, 2025
Clinical Trials Arena
Monument Therapeutics: Monument Therapeutics to trial schizophrenia therapy in partnership with FNIH
Jun 23, 2025
EIN Presswire
Press Release: Monument Therapeutics : Monument Therapeutics Reports Positive Phase I Results for Novel Cognitive Impairment in Schizophrenia Treatment
Feb 25, 2025
tech_eu
Monument Therapeutics: Monument Therapeutics secures 850K to advance schizophrenia treatment with MT1988
Feb 25, 2025
FinSMEs
Monument Therapeutics: Monument Therapeutics Raises 850K in Further Funding
Nov 26, 2024
Yahoo
Monument Therapeutics: Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Nov 19, 2024
FinanzNachrichten
Monument Therapeutics: Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program
Oct 20, 2024
Pulse2.0
Monument Therapeutics: Monument Therapeutics: Precision Neuroscience Company Raises 1 Million
Oct 15, 2024
FinanzNachrichten
Monument Tx: Monument Therapeutics Secures 1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth
Monument Therapeutics Competitors
1
2
3
4
5
6
7
8
9
10